Designation recognizes Vizient-contracted products that bring
improvements to healthcare industry
LONDON, Jan. 30,
2023 /PRNewswire/ -- Smith+Nephew (LSE:SN,
NYSE:SNN), the global medical technology company, today
announces that its LEAF Patient Monitoring System has received
an Innovative Technology designation from Vizient, Inc., the
largest healthcare performance improvement company in the United States. Smith+Nephew exhibited the
LEAF Patient Monitoring System at the Vizient Innovative Technology
Exchange on October 17th in
Dallas, Texas.
Every year, healthcare experts serving on Vizient member-led
councils review select products and technologies for their
potential to enhance clinical care, patient safety, healthcare
worker safety or to improve business operations of healthcare
organizations. Innovative Technology designations are awarded to
previously contracted products to signal to healthcare providers
the impact of these innovations on patient care and business models
of healthcare organizations.
The LEAF Patient Monitoring System is the first wearable,
wireless solution which meets the recommendations in the National
Pressure Injury Advisory Panel (NPIAP) guidelines.1 The
LEAF System is proven to help improve adherence to individualized
turn protocols up to 98%2,3* and has been shown to help
reduce the chance of developing Hospital-acquired pressure injuries
(HAPIs) by 73%.3†
The use of the LEAF System helped improve nursing
efficiencies,4,5 and generated up to $1.8 million estimated annual cost savings in one
facility's critical care units.4,6
"We are very proud to receive the Innovative Technology
designation from Vizient. Pressure injuries are the only hospital
acquired complication on the rise in the US, costing roughly
$11B in preventable treatments, with
dire impact to those patients affected," said Paolo Di Vincenzo, Senior Vice President US
Commercial, Advanced Wound Management for Smith+Nephew. "We will
not settle until we've solved this challenge and are excited for
the role our LEAF Patient Monitoring System will play - fast
becoming a standard of patient care in the U.S. and reducing
facility costs."
The LEAF System indications, contraindications, warnings,
precautions and other important information can be found in the
product's Instructions for Use.
References
† In acutely ill patients in ICU compared to traditional turning
methods from 2.7% to 0.7%; p = 0.012
1. European Pressure Ulcer Advisory Panel, National Pressure
Injury Advisory Panel and Pan Pacific Pressure Injury Alliance.
Prevention and Treatment of Pressure Ulcers/Injuries: Clinical
Practice Guideline. Emily Haesler
(Ed.) EPUAP/NPIAP/PPPIA: 2019. 2. Schutt SC, Tarver C, Pezzani
M. Pilot study: Assessing the effect of continual position
monitoring technology on compliance with patient turning protocols.
Nurs Open. 2017;5(1):21-28.
3. Pickham D, Berte N, Pihulic M, Valdez A, Mayer B, Desai M.
Effect of a wearable patient sensor on care delivery for preventing
pressure injuries in acutely ill adults: A pragmatic randomized
clinical trial (LS-HAPI study). Int J Nurs Stud. 2018;80:12-19.
4. Smith+Nephew 2020.Leveraging novel technology to decrease
hospital-acquired pressure injuries. Internal Report.
EO.AWM.PCS006.001.v1.
5. Rogers M. Reducing Hospital-Acquired Pressure Injuries (HAPI) in
Long-term Acute Care with Turn Cueing Technology. Poster
presented at: American Organization for Nursing Leadership;
March 18- March 21, 2020;
Nashville, Tennessee, USA.
6. Gasparini R, Derisma Q, Hannon R. "Turning" to Technology:
Reducing Hospital Acquired Pressure Injuries in Critical Care with
Visual Turn Cueing. Poster presented at: National Pressure Injury
Advisory Panel Annual Conference; March 10-
March 12, 2021; Virtual Conference.
About Vizient
Vizient represents a diverse membership
that includes academic medical centers, pediatric facilities,
community hospitals, integrated health delivery networks and
non-acute healthcare providers and represents approximately
$130 billion in annual purchasing
volume. Through its Innovative Technology Program, Vizient works
with member-led councils and task forces to evaluate products for
their potential to bring real innovation to healthcare. Vizient may
award a contract to products deemed worthy of the Innovative
Technology designation outside of the competitive bid cycle.
About Smith+Nephew
Smith+Nephew is a portfolio medical
technology company focused on the repair, regeneration and
replacement of soft and hard tissue. We exist to restore people's
bodies and their self-belief by using technology to take the limits
off living. We call this purpose 'Life Unlimited'. Our 18,000
employees deliver this mission every day, making a difference to
patients' lives through the excellence of our product
portfolio, and the invention and application of new technologies
across our three global franchises of Orthopaedics, Sports
Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856,
we now operate in more than 100 countries, and generated annual
sales of $5.2 billion in 2021.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and follow us
on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may
contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of COVID-19, such as the depth and longevity
of its impact, government actions and other restrictive measures
taken in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
COVID-19; economic and financial conditions in the markets we
serve, especially those affecting health care providers, payers and
customers (including, without limitation, as a result of COVID-19);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers
(including, without limitation, as a result of COVID-19);
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that
Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
™ Trademark of Smith+Nephew. Certain marks
registered US Patent and Trademark Office.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/smithnephew-receives-innovative-technology-designation-from-vizient-for-leaf-patient-monitoring-system-301732440.html
SOURCE Smith & Nephew plc